The study introduces a major step forward in lipid management. It encourages all physicians to reassess their approach to assessment and management of clinic patients presenting high LDL-cholesterol levels despite maximum standard of care therapies.
Incredibly robust efficacy performance measures of the investigational agent at completion of 16 weeks of active drug administration. The reported changes in LDL-Cholesterol are particularly robust when considering the Inclusion Criteria for the study. Patients 18-80 years of age were eligible if they had primary HFH or non-heterozygous HFH with atherosclerotic disease, but one of the limitations of the study is that the racial background was not as diverse as intended. What were some of the challenges in achieving a more diverse sample?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.